CapsoVision (CV) EBITDA Margin (2024 - 2025)
CapsoVision recorded quarterly EBITDA Margin of 190.51% in Q4 2025, up 15.95% quarter-over-quarter from 226.65% in Q3 2025, and down 5626.0% year-over-year from 3.45% in Q4 2024.
CapsoVision's EBITDA Margin history runs 2 years deep, the most recent figure standing at 190.51% for Q4 2025.
- In Q4 2025, EBITDA Margin fell 5626.0% year-over-year to 190.51%; the TTM figure through Dec 2025 stood at 174.14% (changed N/A YoY), while the FY2025 annual figure was 188.25%, down 1883.0% from the prior year.
- EBITDA Margin came in at 190.51% for Q4 2025 at CapsoVision, up from 226.65% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 134.24% in Q4 2024 to a low of 226.65% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | CapsoVision | 167.59 Mn | 157.48 Mn | 1.95 Mn | -190.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -190.51% |
| Sep 30, 2025 | -226.65% |
| Jun 30, 2025 | -140.30% |
| Dec 31, 2024 | -134.24% |
| Sep 30, 2024 | -195.65% |
| Jun 30, 2024 | -185.40% |